The author's preferred treatment for spider veins is sclerotherapy, a technique that uses irritants to obliterate the vessel lumen. She reserves laser treatment for vessels too small to sclerose, matting, and patients who refuse sclerotherapy. Treatment is initiated only after ruling out reflux in the larger superficial venous systems or through the perforators. For long lasting and satisfying results, the author recommends multiple treatments, using the lowest concentration of the most effective sclerosant to achieve vessel obliteration with minimal thrombus formation. She presents a guide to pretreatment evaluation, sclerosing solutions, injection technique, and posttreatment care. (Aesthetic Surg J 2008
Featured Operative Technique
T he key to success in the aesthetic treatment of leg veins is identification and control of the source of venous reflux. Unsightly cosmetic leg veins or "spider veins," distinguished from varicose veins on the basis of size, include telangiectasias, or fine red spider veins (<1 mm); venulectasias, or slightly larger, bluish spider veins (<2 mm); and reticular veins (2 to 4 mm; Figure 1 ). The larger leg veins, including the saphenous veins and their tributaries, become varicose as the result of significant venous reflux. The treatment of venous reflux is considered medically necessary compared with the treatment of spider veins, which is viewed as purely aesthetic.
PREOPERATIVE EVALUATION
Reflux in the larger superficial venous systems or through the perforators must be ruled out (or treated) before treating spider veins. Usually, reflux can be assessed by simple circumferential clinical examination of the entire leg, ruling out the presence of bulging varicosities, especially along the paths of the long and short saphenous veins, their major tributaries, and the sites of the common perforators ( Figure 2 ). Once it is determined that the problem is limited to cosmetic spider veins, no further testing is required. 1 If, on physical examination, a question of significant venous reflux arises, noninvasive venous testing is indicated. Doppler ultrasound is useful as a screening tool in patients that demonstrate questionable reflux on clinical exam. In a study evaluating veins that appeared appropriate for cosmetic treatment, 22% of patients with spider veins were found to have superficial venous incompetency, usually in the long saphenous system. 2 One such patient complained of a patch of spider veins on the calf, but was actually found to have a dilated vein close to the saphenofemoral junction upon examination of her thigh ( Figure 3A ). The Doppler probe was placed just below the saphenofemoral junction and, on release of distal compression, augmentation of the Doppler signal for longer than 1 second was heard, indicating reflux. This finding was confirmed by augmentation of the signal with proximal compression applied by a valsalva maneuver ( Figure 3B) .
A physician who is reluctant to use the Doppler ultrasound as a screening tool may simply order a duplex scan to rule out significant venous reflux (in patients in whom physical examination raises this issue). Duplex venous imaging provides not only an audio but also a visual picture of reflux. This software is now available on a laptop computer and is routinely used by phlebologists who treat significant venous reflux.
A patient with significant venous reflux in the saphenous systems, including tributaries or nonsaphenous varicose veins, is referred to a vascular surgeon for endovenous ablation with either radiofrequency or laser or ambulatory phlebectomy. Treatment of significant reflux in these larger veins, while providing a cosmetic benefit to patients, is considered medically necessary.
Once significant reflux is ruled out, treatment of the cosmetic spider veins-consisting of reticular veins, venulectasias, and telangiectasias-is initiated. Treatment depends on the diameter of the vessel; however, typically, different diameters of veins occur together in the same cluster ( Figure 4 ). In fact, this association of reticular veins with spider veins has been studied and it has been shown that 88% of patients with thigh telangiectasias had incompetent reticular veins on Doppler ultrasound and 89% on duplex scanning. 3, 4 
Polidocanol
Choosing a sclerosing agent may be complicated by the fact that these agents tend to enter and leave the market. My favorite sclerosing agent is polidocanol, which is not approved by the US Food and Drug Administration (FDA) but could, until recently, be obtained in the United States from compounding pharmacies. BioForm Medical (San Mateo, CA) has now licensed United States rights to Aethoxysklerol, a sclerosing agent containing polidocanol, which is commonly used in Europe. I believe this agent deserves some consideration if it once again becomes available. It is classified by its mecha- nism of action as a detergent and is weaker than the other commonly used detergent approved by the FDA, sodium tetradecyl sulfate (STS).
Basically, all sclerosing agents are irritants that injure the endothelial surfaces, resulting in obliteration of the vessel lumen ( Figure 5 ). 5 Polidocanol has been widely used for sclerotherapy of spider veins in concentrations of 0.25% to 0.75%. The concentration I have most commonly used is the 0.5% solution (Table 1) . If a patient has a significant number of larger spider veins, including reticular veins, then at the first treatment, I may use a 0.75% solution in these larger spider veins or increase the efficacy of the 0.5% solution by foaming, which I will discuss. The maximum daily dose of polidocanol is 2 mg per kg of body weight. This dose is equivalent to 28 mL of a 0.5% solution in a 70-kg person, which well exceeds the usual amount that would be required in a single treatment session, even in the case of extensive spider vein involvement. 6 Because of the current unavailability of polidocanol, and based on a study in Europe showing that chromated glycerin is superior to polidocanol for sclerotherapy of leg telangiectasias, 7 I have recently begun using glycerin for sclerotherapy of the very small telangiectasias (<1.0 mm in diameter). Glycerin is available in a 72% concentration in the United States from compounding pharmacies because glycerin is used in cerebral edema and acute glaucoma. It has been shown to be as effective as chromated glycerin, which is more widely used in Europe. 8 I dilute the 72% glycerin 2:1 with 1% xylocaine with epinephrine to decrease its viscosity and pain on injection (Table 1) .
Sodium Tetradecyl Sulfate
STS is approved by the FDA and has been used as a sclerosing detergent since the 1940s (except for the period from 2000 to 2002 when its manufacture was discontinued). However, be mindful that STS is a stronger deter- A B C gent than polidocanol and carries an increased risk of adverse sequelae, such as hyperpigmentation and telangiectatic matting. 9 STS in concentrations of 0.1% to 0.15% can be used for sclerotherapy of telangiectasias less than 1 mm in diameter as an alternative to the 72% glycerin diluted 2:1 (if the use of only one agent is desired). For vessels 1 to 3 mm in size, I recommend 0.15% to 0.25% foamed STS solution and 0.25% to 0.5% foamed solution for 3-to 6-mm veins ( Table 1 ). The maximum amount that can be injected at a single treatment session is 10 mL of a 3% solution which, at the low concentrations used for treating spider veins, would rarely be approached in a single session.
Foaming With Air
In patients undergoing sclerotherapy of venulectasias and reticular veins, the efficacy of the detergent can be increased by foaming with air. A 3-mL syringe filled with 0.25 mL of detergent is attached to a second 3-mL syringe filled with 1.25 mL of air, using a double or 3-way stopcock. The amount of air in the syringe is important because the ratio of gas to air is ideally 4:1 to 5:1. The sclerosant is then pushed between the 2 syringes several times until the detergent appears as white foam with tiny bubbles (Figure 6 ). The bubbles of the lipid micelles provide a larger surface area of contact with the endothelium, thus increasing the sclerosing efficacy of the detergent. Foaming also increases effectiveness by inducing vasospasm of the injected vessel so that there is less backflow of blood and dilution of the agent before it can have its sclerosing effect. Because foaming increases the effectiveness of the sclerosing agent, it allows for lower concentrations to be used.
Preparation
Patients usually require 3 30-minute sclerotherapy sessions at 4-to 6-week intervals. This time interval between sessions is optimal for the sclerosant effect to accomplish vessel obliteration. The patient is instructed to avoid applying leg creams on the day of the procedure and to purchase and bring with them 10 to 20 mm Hg graduated compression pantyhose. Photographic documentation of the spider veins is mandatory before treatment. It is difficult to standardize photographic views because the number and locations of the spider veins vary among patients. However, inclusion of a recognizable joint, such as a portion of knee or ankle, helps in orienting the image for later postoperative comparison. 
INJECTIONS
Injections are performed with the patient in the supine position. The legs are prepped with alcohol, which is used not only as an antiseptic, but also to improve visualization of the veins by changing the index of skin refraction. Optimal lighting and magnification are needed. Several different types of transillumination lighting are available to facilitate visualizing the vessels, particularly the reticular veins.
The injections are performed with 30 gauge 0.5-inch disposable needles and 3-mL syringes. The needle is bent to a 30°to 45°angle so that it is parallel to the skin upon entry. Also, the bevel of the needle is turned upward so that the needle may sometimes actually be seen in the lumen of the spider vein ( Figure 7) . The 3-mL syringes are filled with only 1 to 1.5 mL of the sclerosant so that the syringe can be held and the plunger pushed with the same hand, freeing the opposite hand for retraction of the skin. The site of entry into the spider vein is at the source of the reflux if identifiable. A feeding reticular vein, if present, is sclerosed first (Figure 8 ). Along a reticular vein, 0.5 mL of sclerosant is injected at 5.0-cm intervals. The skin is punctured approximately 1 mm from the desired location of entry into the spider vein. The needle is then guided into the spider vein with a gentle but bold puncture. It is not necessary or productive to obtain a blood return except in the deeper reticular veins where the depth is less obvious than the more superficial spider veins. Using low injection pressure and stopping the injection at a particular site when a 1 to 2 cm area is empty of blood are recommended techniques. Continuing the injection beyond this point is likely to increase the incidence of extravasation and telangiectatic matting. 10 Injections are limited to 0.5 mL of the sclerosant at any one site for the same reason.
If a wheal starts to develop at the injection site as the sclerosant is injected, indicating extravasation, then I abort the injection at that site and digitally compress the injection site. This will dilute the extravasated sclerosant by diffusion and, hopefully, avert significant injury to the skin. Only if there is a significant extravasation would I inject a solution of 75 units of hyaluronidase in 3 mL of saline. 11 One of the reasons I prefer polidocanol is that the chance of inducing significant necrosis on extravasation is minimal when 0.5% to 0.75% concentrations are used. For very tiny telangiectasias, 72% glycerin in a 2:1 dilution with lidocaine has become popular because it is even more innocuous upon extravasation, which is difficult to avoid with these very tiny vessels. 8 In most cases of missing a lumen on injection, the needle is deep to the vein. Maintaining digital pressure on this failed site, I would select a second injection site into the spider vein, making sure that the needle is properly bent and as parallel to the skin as possible in order to ensure more superficial placement. The procedure can be tedious, but perseverance is necessary for a good result.
Cotton balls and tape are applied to the injection sites as the treatment progresses. This provides compression and hides the hyperemic reaction in the sclerosed spider vein that develops 30 seconds after the sclerotherapy, which can be perceived by the patient as persistence of the spider vein (Figure 9 ). The detergent is foamed to increase efficacy. One 3-mL syringe is filled with 0.25 mL of 0.5% polidocanol, and the second 3-mL syringe is filled with 1.25 mL of air. Pushing the sclerosant between the 2 syringes several times foams the detergent with a gas to liquid ratio of 5:1, appearing as white foam with tiny bubbles. Figure 7 . A, The injections are performed with 30-gauge half-inch disposable needles and 3-mL syringes filled with only 1 to 1.5 mL of the sclerosant. The needle is bent at a 30°to 45°angle, to be parallel to the skin, with the bevel turned upward. Digital pressure is applied at the previous injection site. B, Using low injection pressure, injecting less than 0.5 mL at each site, and stopping the injection when a 1 to 2 cm area is empty of blood are recommended techniques to decrease the incidence of extravasation and telangiectatic matting. 
Ambulation
The patient is encouraged to walk posttreatment to avoid deep vein thrombosis which, although exceedingly rare, has been reported in 2 patients following sclerotherapy of spider veins. 17, 18 Follow-Up Care
Hyperpigmentation and telangiectatic matting are two of the most common adverse sequelae following sclerotherapy. The goal of the treatment is successful obliteration of the vessel lumen with minimal thrombus formation. A higher incidence of the most common adverse seque-A B Figure 9 . A, Pretreatment view. B, Posttreatment view about 30 seconds after the initial blanching-as the vein is cleared of blood, an intense hyperemic reaction develops.
A B Figure 10 . Evacuation of microthrombi, if present, 1 week following sclerotherapy, is recommended to decrease the incidence of adverse sequelae, including hyperpigmentation and telangiectatic matting. Microthrombi appear as ink-like deposits in the vein. A, The skin is punctured over the microthrombus with a 25-gauge needle. B, The liquefied coagulum is expressed. C, Typical appearance of the removed clot. A few other thrombi still required declotting.
C
lae is felt to occur following excess thrombus formation. 19, 20 I see patients 1 week posttreatment, at which time any coagulum is liquefied, making evacuation possible. Microthrombi appear as ink-like deposits in the vein. If there are any such areas seen, I puncture the skin using a 25-gauge needle and express the clot ( Figure 10 ). If hyperpigmentation develops, I reassure the patient that substantial lightening usually occurs in the first 6 months, although gradual lightening will occur over 24 months. [21] [22] [23] I recommend a topical agent for the treatment of hyperpigmentation, Hiruval-35 (Vimex Pharma), which may be effective in decreasing the hemosiderin deposits that are the primary cause of postsclerotherapy hyperpigmentation. Minocycline should be discontinued during the course of sclerotherapy to avoid minocycline-aggravated postsclerotherapy pigmentation, which may persist for years. 24 I have not used the Q-switched ruby laser or weekly subcutaneous injections with deferoxamine mesylate, both of which have been suggested in the literature for treatment of postsclerotherapy hyperpigmentation. 25, 26 If matting occurs, I first check and sclerose any previously unidentified sources of reflux, such as a feeding reticular vein (Figure 11 ). Once the source of the reflux is controlled, the matting usually will fade. The matting itself may be sclerosed with 0.25% polidocanol or 72% glycerin diluted 2:1, but it will require many treatments. If treatment is unsuccessful, I would then resort to laser treatments with a potassium titanyl phosphate or pulsed-dye laser.
LASER
I reserve use of the laser for 3 indications: (1) cleanup after sclerotherapy for vessels too small to sclerose, (2) matting, and (3) a patient who refuses sclerotherapy. Patients who fear injection pain need to be told that the laser is not painless, especially if they have larger blue spider veins. Although a variety of vascular lasers have been used in the past, the 1064-nm Nd:YAG laser is presently the most widely used, especially for vessels greater than 1 mm in diameter and depth. 27 In general, spider veins of less than 1 to 4 mm respond best to spot sizes of 2.5 to 6.0 mm with fluences of 100 to 22 J/cm 2 and pulse durations of 20 to 60 ms, using larger spot sizes, lower fluences, and longer pulse durations for the larger vessels; and smaller spot sizes, higher fluences and shorter pulse durations for the smaller vessels. 28 In some instances 2 passes over the vessel may be needed for closure. Although some practitioners believe that laser treatment is just as successful as sclerotherapy in the obliteration of spider veins, 29 I agree with the majority of practitioners who have had better clinical success with sclerotherapy than laser treatments. 30, 31 
